Late‐life methionine restriction attenuates neuroinflammation in Alzheimer's disease mice via FGF21 activation in a metabolism‐independent manner

Even when initiated in late life, MR robustly reduces AD pathology via the hepatic FGF21-brain FGFR1 axis, independent of peripheral metabolic changes. These preclinical findings position MR and FGF21-FGFR1 axis as actionable late-life intervention targets with potential for clinical translation.